New Data to Be Presented at Upcoming Congresses Showcase Cerevance's Advanced Clinical Program in Parkinson’s Disease and Deep Pipeline for CNS-based Disorders
Cerevance has announced upcoming presentations of clinical trial results at two major medical conferences in April 2025: the AD/PD™ 2025 in Vienna and the AAN Annual Meeting in San Diego. The key highlight will be the topline results from the Phase 2 ASCEND trial of solengepras (CVN424) as a monotherapy treatment for early-stage Parkinson's disease.
The company will also present first-time data from a Phase 1 trial of CVN293, a novel KCNK13 inhibitor targeting neuroinflammation in CNS diseases. Additional presentations will showcase their proprietary NETSseq platform's potential in identifying novel therapeutic targets for neurodegenerative diseases.
Cerevance ha annunciato prossime presentazioni dei risultati di studi clinici in due importanti conferenze mediche nell'aprile 2025: l'AD/PD™ 2025 a Vienna e l'AAN Annual Meeting a San Diego. Il punto saliente sarà il risultato principale del trial di Fase 2 ASCEND di solengepras (CVN424) come trattamento monoterapico per il morbo di Parkinson in fase iniziale.
La società presenterà anche dati inediti da un trial di Fase 1 di CVN293, un nuovo inibitore KCNK13 che mira alla neuroinfiammazione nelle malattie del SNC. Ulteriori presentazioni mostreranno il potenziale della loro piattaforma proprietaria NETSseq nell'identificare nuovi obiettivi terapeutici per le malattie neurodegenerative.
Cerevance ha anunciado próximas presentaciones de resultados de ensayos clínicos en dos importantes conferencias médicas en abril de 2025: el AD/PD™ 2025 en Viena y la Reunión Anual de la AAN en San Diego. El punto destacado será el resultado principal del ensayo de Fase 2 ASCEND de solengepras (CVN424) como tratamiento monoterapéutico para la enfermedad de Parkinson en etapas tempranas.
La compañía también presentará datos por primera vez de un ensayo de Fase 1 de CVN293, un nuevo inhibidor de KCNK13 que apunta a la neuroinflamación en enfermedades del SNC. Presentaciones adicionales mostrarán el potencial de su plataforma propietaria NETSseq para identificar nuevos objetivos terapéuticos para enfermedades neurodegenerativas.
세레반스는 2025년 4월 비엔나에서 열리는 AD/PD™ 2025와 샌디에이고에서 열리는 AAN 연례 회의에서 임상 시험 결과에 대한 발표를 예정하고 있다고 발표했습니다. 주요 하이라이트는 초기 단계 파킨슨병 치료를 위한 단독 요법으로서의 솔렌게프라스(CVN424)의 2상 ASCEND 시험의 주요 결과입니다.
회사는 또한 CNS 질환의 신경 염증을 표적으로 하는 새로운 KCNK13 억제제인 CVN293의 1상 시험에서의 최초 데이터를 발표할 예정입니다. 추가 발표에서는 신경퇴행성 질환을 위한 새로운 치료 표적을 식별하는 데 있어 그들의 독점 NETSseq 플랫폼의 잠재력을 보여줄 것입니다.
Cerevance a annoncé des présentations à venir des résultats d'essais cliniques lors de deux grandes conférences médicales en avril 2025 : l'AD/PD™ 2025 à Vienne et la Réunion Annuelle de l'AAN à San Diego. Le point fort sera les résultats préliminaires de l'essai de Phase 2 ASCEND de solengepras (CVN424) en tant que traitement monothérapeutique pour la maladie de Parkinson à un stade précoce.
L'entreprise présentera également pour la première fois des données d'un essai de Phase 1 de CVN293, un nouvel inhibiteur KCNK13 ciblant la neuroinflammation dans les maladies du SNC. Des présentations supplémentaires mettront en avant le potentiel de leur plateforme propriétaire NETSseq pour identifier de nouvelles cibles thérapeutiques pour les maladies neurodégénératives.
Cerevance hat die bevorstehenden Präsentationen von Ergebnissen klinischer Studien auf zwei großen medizinischen Konferenzen im April 2025 angekündigt: dem AD/PD™ 2025 in Wien und dem AAN-Jahrestreffen in San Diego. Das Hauptaugenmerk wird auf den vorläufigen Ergebnissen der Phase-2-Studie ASCEND zu Solengepras (CVN424) als Monotherapie zur Behandlung der frühen Parkinson-Krankheit liegen.
Das Unternehmen wird auch erstmals Daten aus einer Phase-1-Studie zu CVN293 präsentieren, einem neuartigen KCNK13-Inhibitor, der auf Neuroinflammation bei Erkrankungen des ZNS abzielt. Weitere Präsentationen werden das Potenzial ihrer proprietären NETSseq-Plattform zur Identifizierung neuer therapeutischer Ziele für neurodegenerative Erkrankungen aufzeigen.
- Multiple clinical trial results to be presented across two major medical conferences
- Advancement of Phase 2 trial for early-stage Parkinson's disease treatment
- Progress in Phase 1 trial for novel KCNK13 inhibitor targeting neuroinflammation
- None.
- Topline results from Phase 2 ASCEND trial of solengepras as a monotherapy treatment for early-stage Parkinson’s to be presented
- First presentation of data from Phase 1 trial of novel KCNK13 inhibitor for CNS diseases targeting neuroinflammation
- Additional meeting presentations highlight potential of proprietary NETSseq platform to identify novel therapeutic targets for neurodegenerative diseases
BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative, psychiatric, and central nervous system-controlled metabolic disorders, today announced upcoming presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2025) being held April 1-5 in Vienna, and the American Academy of Neurology (AAN) Annual Meeting being held April 5-9 in San Diego.
Details of the oral presentation at AD/PD™ 2025 are as follows:
Title: Results of ASCEND: A Phase 2 Trial of Solengepras (CVN424) as an Investigational Monotherapy for Treatment of Early Parkinson’s Disease
- Presenter: Aaron L. Ellenbogen, DO, MPH
- Session Date/Time: Tuesday, April 1, 2025, 1:15 p.m. CEST / 4:15 a.m. PT
Details of the poster presentations at the AAN 2025 Annual Meeting are as follows:
Title: NETSseq Identifies Novel Therapeutic Targets for Neurodegenerative Diseases (#3592)
- Presenter: Sagar Vaidya, M.D., Ph.D.
- Session Date/Time: Sunday, April 6, 2025, 11:45 a.m. PT
Title: A First-in-Human Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN293, an Investigational Inhibitor of KCNK13 Targeting NLRP3-Mediated Neuroinflammation (#3282)
- Presenter: Sagar Vaidya, M.D., Ph.D.
- Session Date/Time: Tuesday, April 8, 2025, 8 a.m. PT
Title: Solengepras (CVN424): A Novel GPR6 Inhibitor in Clinical Development as an Investigational Therapy for Parkinson’s Disease (#2892)
- Presenter: Kelvin L. Chou, M.D., FAAN
- Session Date/Time: Wednesday, April 9, 2025, 8 a.m. PT
About Cerevance
Cerevance is focused on advancing cell type-specific therapies for the treatment of neurodegenerative, psychiatric, and central nervous system-controlled metabolic disorders. Our proprietary platform, Nuclear Enriched Transcript Sort sequencing (NETSseq), allows us to identify targets that are expressed at very low levels, that are present in rare cell types, or that change over time as a disease progresses. Our most advanced investigational treatment, solengepras, is currently in Phase 3 development and has the potential to be a first-in-class, oral non-dopaminergic therapy for both motor and non-motor symptoms of Parkinson's disease. Our second investigational therapy, CVN766, is designed to be a highly selective oral antagonist of the orexin 1 receptor for the potential treatment of binge eating disorder and schizophrenia. Our third investigational treatment, CVN293, is a highly selective investigational oral inhibitor targeting potassium two pore domain channel subfamily K member 13 (KCNK13). CVN293 represents a potentially novel intervention point for neurodegenerative disorders and obesity. For more information, please visit www.cerevance.com and follow us on LinkedIn and X.
Contacts
Cerevance:
Johnna Simoes, ir@cerevance.com
Media:
April Dovorany, adovorany@realchemistry.com, +1-262-909-8739
FAQ
What are the key findings from Cerevance's Phase 2 ASCEND trial for Parkinson's disease (CRVN)?
What is the significance of Cerevance's CVN293 Phase 1 trial presentation (CRVN)?
When and where will Cerevance present its clinical trial results in 2025 (CRVN)?
What therapeutic areas is Cerevance's pipeline focusing on (CRVN)?
